Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
MR MRK Merck & Co., Inc. FY ended Jan 31, 2026 | $148.35 | $366.00B | $392.48B | $65.01B | $28.05B | $18.25B | 20.38x | 5.63x | 13.37x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 12.78x | 5/5 | -$17.40B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.79x | 5/5 | $54.23B | $47.21 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 37.51x | 5/5 | -$131.84B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
OG OGN Organon & Co. FY ended Feb 17, 2026 | $13.76 | $3.61B | $13.79B | $6.22B | $1.29B | $187.00M | 19.11x | 0.58x | 10.69x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
MR MRK Merck & Co., Inc. FY ended Jan 31, 2026 | $148.35 | $366.00B | $392.48B | $65.01B | $28.05B | $18.25B | 20.38x | 5.63x | 13.37x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 12.78x | 5/5 | -$17.40B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.79x | 5/5 | $54.23B | $47.21 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 37.51x | 5/5 | -$131.84B | — | Target fundamentals do not produce a usable positive equity value. |
